You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Genzyme reports encouraging data for Gaucher disease drug candidate

Genzyme, the Cambridge biotechnology division of French drug maker Sanofi SA, reported positive data for an experimental drug for Gaucher disease, a rare genetic disorder that can cause swelling of the liver and spleen.

Genzyme has an existing Gaucher disease drug on the market called Cerezyme. In 2008, when Genzyme was still a public company, Cerezyme accounted for $1.24 billion in revenues, or 30 percent of total company revenues. (Cerezyme revenues in 2009 and 2010 were hurt by production problems at the company’s facility in Allston. Sanofi bought Genzyme for $20.1 billion in 2011, and Genzyme no longer breaks out drug revenues.)

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week